NIH news release.The trial is currently in its third phase and is designed to expand its testing to multiple kinds of synthetic antibody treatments.
If the treatment shows promise, additional volunteers can enroll in the middle of testing, the news release said.Approximately 300 volunteers who have been hospitalized with mild to moderate COVID-19 symptoms with fewer than 13 days of symptoms will be initially enrolled into the study.RELATED: After 28 employees test positive for COVID-19 at Westlake Food 4 Less, workers demand better protection The trial is one of the four ongoing studies being conducted by the NIH with assistance from Operation Warp Speed, a U.S.